ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 607

Clinical and Functional Response to Tofacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from the ORAL Strategy Trial

Tsutomu Takeuchi1, Josef S. Smolen2, Roy Fleischmann3, Noriko Iikuni4, Haiyun Fan5, Koshika Soma6, Ermeg Akylbekova7 and Tomohiro Hirose8, 1Keio University, Tokyo, Japan, 2Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 3Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Collegeville, PA, 6Pfizer Inc, Groton, CT, 7IQVIA, Durham, NC, 8Pfizer Japan Inc, Tokyo, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis (RA) and tofacitinib

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055), a 12-month, global, Phase 3b/4 study, demonstrated that in patients with RA and an inadequate response to MTX, tofacitinib + MTX was non-inferior to adalimumab + MTX, while tofacitinib monotherapy was not non-inferior to either combination based on American College of Rheumatology (ACR)50 response rates at Month 6.1 This post hoc analysis aimed to assess the clinical and functional efficacy across treatments in the ORAL Strategy trial using cumulative probability plots.

Methods: Efficacy was evaluated between patients who received tofacitinib 5 mg twice daily (BID) as monotherapy (N=384), tofacitinib 5 mg BID + MTX (N=376), and adalimumab 40 mg subcutaneously once every 2 weeks + MTX (N=386) based on ACR responses and changes from baseline in Health Assessment Questionnaire-Disability Index (ΔHAQ-DI) at Month 12. Cumulative probability plots for ACR-n (where ACR is the % improvement from baseline in ACR components, and n represents the minimum % achieved by each patient) and ΔHAQ-DI are presented. The area under the curve (AUC) was calculated for ACR-n up to Month 12 (in months), and an analysis of covariance model was used to assess treatment effects in terms of the AUC of ACR-n at Month 12; there was no adjustment for multiplicity for this post hoc analysis.

Results: The cumulative probability plots of ACR responses at Month 12 indicated that the proportion of patients who achieved responses of ACR20, ACR50, and ACR70 was similar for tofacitinib + MTX and adalimumab + MTX, but was numerically smaller for tofacitinib monotherapy (Figure A). Responses of approximately ≥ACR80 were achieved by a similar proportion of patients in each treatment group. Least squares mean (standard error) AUC of ACR-n up to Month 12 (in months) was similar for tofacitinib + MTX (437 [35]) and adalimumab + MTX (402 [35]), but was smaller for tofacitinib monotherapy (319 [35]; p<0.05; data not shown). The cumulative probability plots of ΔHAQ-DI suggested that, in general, reductions from baseline in HAQ-DI were similar across treatment groups (Figure B), although a slightly higher proportion of patients who received tofacitinib monotherapy reported an increase in HAQ-DI vs other treatments.

Conclusion: These data support the primary ORAL Strategy findings,1 indicating that in patients with RA, clinical efficacy, based on ACR response, was generally similar for tofacitinib + MTX and adalimumab + MTX, while a smaller proportion of patients who received tofacitinib monotherapy achieved ACR response in general, and particularly for <ACR80. Functional efficacy, based on ΔHAQ-DI, was generally similar across all treatment groups. Cumulative probability analyses for CDAI will be further evaluated.

1. Fleischmann et al. Lancet 2017; 390: 457–68.


Disclosure: T. Takeuchi, AbbVie, Asahi-kasei, Astellas, AYUMI, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe Nipponkayaku, Novartis, Pfizer Japan Inc, Takeda, 2,AbbVie, Astellas, AstraZeneca, Chugai, Eli Lilly Japan, GSK, Janssen, Mitsubishi-Tanabe, Nipponkayaku, Novartis, Taiho, Taisho Toyama, UCB Japan, 5,AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Diaichi-Sankyo, Eisai, Mitsubishi-Tanabe, Novartis, Pfizer Japan Inc, Sanofi, Takeda, Teijin, 8; J. S. Smolen, AbbVie, AstraZeneca, Eli Lilly, Janssen, MSD, Pfizer Inc, Roche, 2,AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, GSK, ILTOO, Janssen, Medimmune, MSD, Novartis, Pfizer Inc, Roche, Samsung, Sanofi, UCB, 5; R. Fleischmann, Pfizer Inc, 2,Pfizer Inc, 5,Pfizer Inc, 8; N. Iikuni, Pfizer Inc, 1,Pfizer Inc, 3; H. Fan, Pfizer Inc, 1,Pfizer Inc, 3; K. Soma, Pfizer Inc, 1,Pfizer Inc, 3; E. Akylbekova, IQVIA, a paid contractor to Pfizer, 3; T. Hirose, Pfizer Inc, 1,Pfizer Inc, 3.

To cite this abstract in AMA style:

Takeuchi T, Smolen JS, Fleischmann R, Iikuni N, Fan H, Soma K, Akylbekova E, Hirose T. Clinical and Functional Response to Tofacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from the ORAL Strategy Trial [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/clinical-and-functional-response-to-tofacitinib-and-adalimumab-in-patients-with-rheumatoid-arthritis-probability-plot-analysis-of-results-from-the-oral-strategy-trial/. Accessed December 11, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-functional-response-to-tofacitinib-and-adalimumab-in-patients-with-rheumatoid-arthritis-probability-plot-analysis-of-results-from-the-oral-strategy-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.